Lakefront Biotherapeutics (GLPGF) EBT (2014 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported EBT for 13 consecutive years, with -$50.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 128.49% year-over-year to -$50.6 million in Q2 2026; TTM through Jun 2026 was $350.2 billion, a 10514.75% increase from a year earlier, with the FY2025 full-year figure at $339.9 billion, up 10280.47% from the prior year.
• EBT was -$50.6 million for Q2 2026 at Lakefront Biotherapeutics, down from $16.3 million in the prior quarter.
• Over five years, EBT peaked at $350.8 billion in Q4 2025 and troughed at -$72.3 billion in Q4 2022.
• A 5-year average of $15.6 billion and a median of -$15.1 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT sank 1529135.55% in 2022 and surged 10817.69% in 2025, its largest moves.
• Over 5 years, EBT stood at -$72.3 billion in 2022, then soared by 108.3% to $6.0 billion in 2023, then plunged by 154.55% to -$3.3 billion in 2024, then surged by 10817.69% to $350.8 billion in 2025, then sank by 100.01% to -$50.6 million in 2026.
• The last three EBT figures came in at -$50.6 million (Q2 2026), $16.3 million (Q1 2026), and $350.8 billion (Q4 2025), per Business Quant data.